Subsequently, IHC analysis of tumour sections showed reduced staining of the proliferation marker Ki-67 and attenuated α-SMA staining, as well as decrease in the resultant expression of the lymphatic marker LYVE1, in the group co-injected with CAFs Gli1-shRNA compared with that of the group co-injected with CAFs shNC. This evidence concerns the gene MKI67 and neoplasm.